Effects of Advanced Glycation End-products on the Proliferation and Fibronectin Production of Smooth Muscle Cells

• Sakata Noriyuki

  Second Department of Pathology, School of Medicine, Fukuoka University

• Meng Jing

  Second Department of Pathology, School of Medicine, Fukuoka University

• Takebayashi Shigeo

  Second Department of Pathology, School of Medicine, Fukuoka University

抄録

The aim of this study was to evaluate the effects of advanced glycation end-products (AGEs) on the proliferative activity and fibronectin production of smooth muscle cells (SMCs). AGE-bovine serum albumin (AGE-BSA) was prepared by incubation with D-glucose at 37°C for 60 days. Cultured SMCs were obtained from explants isolated from porcine abdominal aorta and used between passages 3 and 10. The proliferative activity of SMCs was examined by MTT (3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyl tetrazolium bromide) assay and by incorporation of ³H-thymidine into DNA. Fibronectin production was assessed by competitive ELISA assay for both fibronectin secreted into the culture medium (M-FN) and cell-associated fibronectin (C-FN), i.e., both intra- and peri-cellular fibronectin. The MTT assay revealed that AGE-BSA did not produce any change in optical density (A₅₇₀) of SMCs at concentrations of up to 20 μg/ml, but decreased that of SMCs at a concentration of 40μg/ml. The addition of PDGF (5 ng/ml) induced an increase in ³H-thymidine incorporation into DNA of quiescent SMCs, while the addition of AGE-BSA (20 μg/ml) had no effect. In contrast, AGE-BSA significantly increased C-FN of SMCs (30.8±8.58 ng/μg TP), compared to unmodified BSA (16.5+4.19 ng/μg TP). However, no difference in M-FN levels was observed between cells treated with AGE-BSA and unmodified BSA. The addition of anti-transforming growth factor (TGF) -β antibody restored the levels of C-FN in SMCs cultured in 20 μg/ml of AGE-BSA, suggesting that TGF-β might act as an intermediate factor in AGE-induced fibronectin production by SMCs. Our results suggest that interaction of AGE-modified proteins with SMCs may play a role in the development of atherosclerosis in diabetic and non-diabetic patients.

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ

  Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ 7 (3), 169-176, 2000

  一般社団法人 日本動脈硬化学会

キーワード

• Advanced glycation end-products (AGEs)
• Fibronectin
• Proliferation
• Smooth muscle cells (SMCs)

詳細情報

• CRID: 1390282679410446592
• NII論文ID: 130004304703
• NII論文ID: 10009470630
• NII書誌ID: AA11018976
• DOI: 10.5551/jat1994.7.169
• COI: 1:CAS:528:DC%2BD3MXktlelsbw%3D
• ISSN: 18803873
• ISSN: 13403478
• PubMed: 11480459
• Web Site: https://www.jstage.jst.go.jp/article/jat1994/7/3/7_3_169/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2001164047
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可